IPO registrations (S-1, F-1) · Registrants
Zymeworks BC Inc.
- SEC CIK
- 1403752 · filings on EDGAR ↗
- Name on the registration
- Zymeworks Inc.
- Former names
- Zymeworks Inc. (2009–2022); Zymeworks Inc (2007–2007)
- Registration
- Form F-1, first filed 2017-04-03, last 2017-04-24; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2017-04-28; declared effective 2017-04-27
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- A1
- Business address
- SUITE 800 - 114 EAST 4TH AVENUE, Vancouver, A1 V5T 1G4
- EDGAR entity type
- operating
- Insiders and CEO pay
- Zymeworks BC Inc. on the corporate pages
Offering terms
- Proposed price range
- $13.00–$16.00 per share (F-1/A filed 2017-04-24)
- Final price
- $13.00 per share, within the range (424B4 filed 2017-04-28, an initial public offering)
- Shares sold
- 4,500,000
- Gross proceeds
- $58,500,000 before underwriting discounts and any over-allotment option
- Listing
- TSX under the symbol ZYME
- Lead underwriters
- Citigroup; Barclays; Wells Fargo
- Syndicate
- Canaccord Genuity
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Zymeworks Inc. EXACT (CIK (EXACT))
- SEC filer: Zymeworks BC Inc. EXACT (CIK (EXACT))
Filings 7
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-04-03 | F-1 | F-1 (foreign registration) | Zymeworks Inc. | 0001193125-17-107264 ↗ |
| 2017-04-17 | F-1/A | F-1/A (amendment) | Zymeworks Inc. | 0001193125-17-125105 ↗ |
| 2017-04-24 | F-1/A | F-1/A (amendment) | Zymeworks Inc. | 0001193125-17-133751 ↗ |
| 2017-04-27 | EFFECT | EFFECT (declared effective) | Zymeworks Inc. | 9999999995-17-001008 ↗ |
| 2017-04-28 | 424B4 | 424B4 (final prospectus) | Zymeworks Inc. | 0001193125-17-148105 ↗ |
| 2018-05-24 | EFFECT | EFFECT (declared effective) | Zymeworks Inc. | 9999999995-18-001338 ↗ |
| 2019-01-31 | EFFECT | EFFECT (declared effective) | Zymeworks Inc. | 9999999995-19-000046 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-04-24 | F-1/A | registration statement | $13.00–$16.00 | 4,500,000 | - | NYSE ZYME | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2017-04-28 | 424B4 | final prospectus | $13.00 | 4,500,000 | $58,500,000 | TSX ZYME | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| LILLY ELI & CO | Other; TenPercentOwner | 15 | 2018–2019 | ||
| Bedford Nick | Director | 2 | 2019 | ||
| HAUSMAN DIANA | Officer | Chief Medical Officer | 11 | 2019–2021 | |
| Hillan Kenneth J. | Director | 4 | 2019–2021 | ||
| Klompas Neil A | Officer | Chief Financial Officer; Chief Operating Officer; Chief Operating Officer & CFO | 17 | 2019–2022 | |
| Polverino Anthony J. | Officer | Chief Scientific Officer | 12 | 2019–2022 | |
| Poon David Kai Yuen | Officer | See Remarks | 3 | 2019 | |
| RENTON HOLLINGS | Director | 4 | 2019–2021 | ||
| Sacks Natalie | Director | 4 | 2019–2021 | ||
| Tehrani Ali | Director,Officer | Chief Executive Officer | 11 | 2019–2021 | |
| Zoth Lota S. | Director | 4 | 2019–2021 | ||
| Cox Troy | Director | 4 | 2019–2021 | ||
| Mahony Susan | Director | 3 | 2019–2021 | ||
| O'Driscoll Kathryn | Officer | Chief People Officer | 8 | 2019–2021 | |
| 667, L.P. | Director | 3 | 2020 | ||
| Baker Bros. Advisors (GP) LLC | Director | 3 | 2020 | ||
| BAKER BROS. ADVISORS LP | Director | 3 | 2020 | ||
| Baker Brothers Life Sciences LP | Director | 3 | 2020 | ||
| BAKER FELIX | Director | 3 | 2020 | ||
| BAKER JULIAN | Director | 3 | 2020 | ||
| Neu Kelvin | Director | 2 | 2020–2021 | ||
| Priour James | Officer | Chief Commercial Officer | 4 | 2021 | |
| Josephson Neil | Officer | Chief Medical Officer; Interim Chief Medical Officer | 8 | 2021–2022 | |
| Galbraith Kenneth | Director,Officer | Chair, President & CEO | 2 | 2022 | |
| Astle Christopher | Officer | SVP & Chief Financial Officer | 2 | 2022 | |
| Moore Paul Andrew | Officer | Chief Scientific Officer | 2 | 2022 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2016-01-21 | Zymeworks Inc. | Biotechnology | $75,000,003 | $61,517,859 | 15 | 1 |
| 2015-02-27 | Zymeworks Inc. | Biotechnology | $1,785,700 | $1,785,700 | 1 | 1 |
| 2015-01-08 | Zymeworks Inc. | Biotechnology | $8,601,260 | $8,601,260 | 1 | 1 |
| 2014-11-04 | Zymeworks Inc. | Biotechnology | $23,988,700 | $23,988,700 | 1 | 2 |
| 2014-02-14 | Zymeworks Inc. | Biotechnology | $1,025,752 | $1,025,752 | 3 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Zymeworks Inc. | Form D private offerings | CIK (EXACT) | |
| SEC filer | Zymeworks BC Inc. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, A1 first:
- ONCOGENEX TECHNOLOGIES INC A1
- Aspreva Pharmaceuticals CORP A1
- Lexaria Bioscience Corp. A1
- BetterLife Pharma Inc. A1
- ABATTIS BIOCEUTICALS CORP A1
- BriaCell Therapeutics Corp. A1
- Old API Wind-down Ltd. A1
- AbCellera Biologics Inc. A1
- BODY & MIND INC. A1
- XORTX Therapeutics Inc. A1
In other datasets, the same topic (Health) in A1:
- Form D issuer: 1219014 B.C. Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health